Table III.
RFS and OS analyses using a multivariate Cox proportional hazards model.
| RFS | OS | |||
|---|---|---|---|---|
| Parameter | HR (95% CI) | aP | HR (95% CI) | aP |
| Age, ≥45 years vs. <45 years | 1.346 (0.695, 2.604) | 0.378 | 0.625 (0.283, 1.363) | 0.238 |
| Gender, male vs. female | 1.124 (0.720, 1.753) | 0.607 | 1.328 (0.715, 2.468) | 0.369 |
| Tumor classification, T1, T2, T3, T4 | 1.148 (0.913, 1.444) | 0.238 | 1.322 (0.939, 1.860) | 0.110 |
| Lymph node status, N0, N1, N2, N3 | 1.261 (0.965, 1.648) | 0.090 | 1.549 (1.054, 2.277) | 0.026 |
| Metastasis status, M1 vs. M0 | 0.139 (0.019, 1.027) | 0.053 | 4.216 (1.703, 10.435) | 0.002 |
| Pre-treatment EBV-DNA, ≥1500 vs. <1500 copies/ml | 1.954 (1.080, 3.534) | 0.027 | 1.827 (0.787, 4.237) | 0.161 |
| Post-treatment EBV-DNA, positive vs. negative | 2.306 (1.427, 3.727) | 0.001 | 1.432 (0.708, 2.894) | 0.318 |
a
P-values were determined using the Wald test. RFS, relapse-free survival; OS, overall survival; RFS, relapse-free survival; OS, overall survival; T, tumor; N, nodal; M, metastasis; EBV, Esptein-Barr virus.